Abstract
Exon-skipping efficacy of phosphorodiamidate morpholino oligomers (Morpholinos) has been demonstrated in a proof-of-concept clinical trial for Duchenne muscular dystrophy (DMD). Systemic delivery of Morpholinos can be significantly enhanced by conjugating them to cell-penetrating peptides. The improved efficacy has been demonstrated in DMD animal models, including mdx mice and utrophin–dystrophin double-knockout mice. Compared to unconjugated Morpholinos, far lower doses of the peptide–Morpholino conjugates can restore dystrophin sufficiently to reduce disease pathology, increase skeletal and cardiac muscle functions and prolong survival of animals. In addition, the conjugates enter cardiomyocytes in useful quantities and improve heart functions. Here, an experimental protocol for making Tat peptide–Morpholino conjugate is described.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Summerton J, Weller D (1997) Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid Drug Dev 7:187–195
Hudziak RM, Barofsky E, Barofsky DF, Weller DL, Huang SB, Weller DD (1996) Resistance of morpholino phosphorodiamidate oligomers to enzymatic degradation. Antisense Nucleic Acid Drug Dev 6:267–272
Youngblood DS, Hatlevig SA, Hassinger JN, Iversen PL, Moulton HM (2007) Stability of cell-penetrating peptide-morpholino oligomer conjugates in human serum and in cells. Bioconjug Chem 18:50–60
Bill BR, Petzold AM, Clark KJ, Schimmenti LA, Ekker SC (2009) A primer for morpholino use in zebrafish. Zebrafish 6:69–77
Yin H, Moulton HM, Seow Y, Boyd C, Boutilier J, Iverson P et al (2008) Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function. Hum Mol Genet 17:3909–3918
Alter J, Lou F, Rabinowitz A, Yin H, Rosenfeld J, Wilton SD et al (2006) Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat Med 12: 175–177
Yokota T, Lu QL, Partridge T, Kobayashi M, Nakamura A, Takeda S et al (2009) Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs. Ann Neurol 65:667–676
Kinali M, Arechavala-Gomeza V, Feng L, Cirak S, Hunt D, Adkin C et al (2009) Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol 8:918–928
Moulton HM, Hase MC, Smith KM, Iversen PL (2003) HIV Tat peptide enhances cellular delivery of antisense morpholino oligomers. Antisense Nucleic Acid Drug Dev 13:31–43
Moulton HM, Moulton JD (2010) Morpholinos and their peptide conjugates: therapeutic promise and challenge for Duchenne muscular dystrophy. Biochim Biophys Acta 1798:2296–303
Moulton HM, Nelson MH, Hatlevig SA, Reddy MT, Iversen PL (2004) Cellular uptake of antisense morpholino oligomers conjugated to arginine-rich peptides. Bioconjug Chem 15:290–299
Wu B, Moulton HM, Iversen PL, Jiang J, Li J, Spurney CF et al (2008) Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer. Proc Natl Acad Sci USA 105:14814–14819
Yin H, Moulton HM, Betts C, Seow Y, Boutilier J, Iverson PL et al (2009) A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice. Hum Mol Genet 18:4405–4414
Goyenvalle A, Babbs A, Powell D, Kole R, Fletcher S, Wilton SD et al (2009) Prevention of dystrophic pathology in severely affected dystrophin/utrophin-deficient mice by morpholino-oligomer-mediated exon-skipping. Mol Ther 18:198–205
Sazani P, Blouch R, Weller D, Leow S, Kole R, Shrewsburry S (2009) AVI 5038: initial efficacy and safety evaluation in cynomolgus monkeys. Treat-NMD/NIH conference 2009. Brussels, Belgium
Abes S, Moulton HM, Clair P, Prevot P, Youngblood DS, Wu RP et al (2006) Vectorization of morpholino oligomers by the (R-Ahx-R)4 peptide allows efficient splicing correction in the absence of endosomolytic agents. J Control Release 116: 304–313
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Moulton, H.M. (2012). Cell-Penetrating Peptides Enhance Systemic Delivery of Antisense Morpholino Oligomers. In: Aartsma-Rus, A. (eds) Exon Skipping. Methods in Molecular Biology, vol 867. Humana Press. https://doi.org/10.1007/978-1-61779-767-5_26
Download citation
DOI: https://doi.org/10.1007/978-1-61779-767-5_26
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-61779-766-8
Online ISBN: 978-1-61779-767-5
eBook Packages: Springer Protocols